Last reviewed · How we verify
CINACALCET HYDROCHLORIDE
At a glance
| Generic name | CINACALCET HYDROCHLORIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2004 |
Approved indications
Common side effects
- Nausea
- Vomiting
- Hypocalcemia
- Hypersensitivity reactions
- Rash
Serious adverse events
- Seizures
- Gastrointestinal hemorrhage
- Multi-organ failure
- Cardiovascular events
- Metastatic carcinoma
Key clinical trials
- The Trial of SHR6508 in Secondary Hyperparathyroidism (PHASE3)
- Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism (PHASE3)
- Novel Combination Therapy for Osteoporosis in Men (PHASE4)
- Effect of Whole-body Vibration Training in Patients With Renal Dialysis (NA)
- Calcium Isotope Ratios to Assess Calcium Bone Balance in Dialysis Children Receiving Cinacalcet
- DePTH: De-emphasize PTH (PHASE2)
- Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients (PHASE1, PHASE2)
- A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |